World Health Organization Sounds Warning Over Acute Scarcity of Weight-Loss Jabs
Fewer than 10% of people that would benefit from weight-loss injections like Wegovy can access them, caution the World Health Organization as it publishes its initial advice on the therapies.
With more than one billion people worldwide currently classified as obese, it is advocating for increased and just access to GLP-1 medication.
According to estimates, over two billion could be obese by 2030 if no action is taken.
"The new guidelines affirms that obesity is a lifelong illness that can be treated with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the treatments that can assist patients in reducing substantial body mass, says the organization.
Skinny Jab Scarcity
Despite the present best projected case, the supply of these medications would only suffice for approximately 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice calls on countries and companies to widen access, via measures such as voluntary licensing.
Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is set to lapse in a number of countries in 2026.
How Obesity Jabs Function
These medications imitate a body's own hormone to reduce digestion speed, curb appetite and boost the sense of being full so users consume fewer calories.
Individuals commonly begin shedding pounds after several weeks of beginning the regular doses.
Evidence indicates patients may see weight return within a year of halting the drug, as their normal hunger come back.
To be above a healthy weight elevates your chance for developing diseases, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight impacts individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, as per the health agency.
